The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: A double-blind, randomized, placebo-controlled trial

Neurogastroenterology and Motility

Volumn 20, Issue 3, 2008, Pages 220-227

  Choung, R S ^a   Cremonini, F ^a   Thapa, P ^b   Zinsmeister, A R ^b   Talley, N J ^a,c  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c Davis Building ^*  (United States)

Author keywords

Antidepressants; Gastric emptying; Gastric satiation

Indexed keywords

ENSURE; MIRTAZAPINE; NORTRIPTYLINE; OCTANOIC ACID; PLACEBO;

ADULT; ANXIETY DISORDER; ARTICLE; BODY MASS; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEADACHE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NUTRITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SCORING SYSTEM; SEX DIFFERENCE; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; STOMACH DISCOMFORT; STOMACH EMPTYING; STOMACH MOTILITY; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BREATH TESTS; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; HUMANS; MALE; MIANSERIN; MIDDLE AGED; NORTRIPTYLINE; OCTANOIC ACIDS; POSTPRANDIAL PERIOD; SAMPLE SIZE; SATIATION;

EID: 38849206830     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.01029.x     Document Type: Article

References (45)

1. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992 102 : 1259 68.
2. Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995 40 : 584 9.
3. Nyren O, Lindberg G, Lindstrom E, Marke LA, Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics 1992 1 : 312 24.
4. Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med 1988 108 : 865 79.
5. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006 doi: 10.1002/14651858.CD001960.pub3.
6. Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989 96 : 704 12.
7. Choung RS, Talley NJ, Peterson J et al. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007 19 : 180 7.
8. Moayyedi P, Soo S, Deeks J et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006 doi: 10.1002/14651858. CD002096.pub4.
9. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996 31 : 318 25.
10. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003 125 : 19 31.
11. Halpert A, Dalton CB, Diamant NE et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005 100 : 664 71.
12. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000 108 : 65 72.
13. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001 57 : 161 78.
14. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998 93 : 160 5.
15. Camilleri M, Talley NJ. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil 2004 16 : 135 42.
16. Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003 284 : G130 7.
17. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999 60 (Suppl. 4 4 11. Discussion 12 3.
18. Magni G. The use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs 1991 42 : 730 48.
19. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998 275 : G460 6.
20. Cannon RO III., Quyyumi AA, Mincemoyer R et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994 330 : 1411 7.
21. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 2005 6 : 631 41.
22. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000 38 : 461 74.
23. Miranda A, Peles S, McLean PG, Sengupta JN. Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia. Pain 2006 126 : 54 63.
24. Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ III. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990 65 : 1456 79.
25. Yue QY, Zhong ZH, Tybring G et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998 64 : 384 90.
26. Lee JS, Camilleri M, Zinsmeister AR et al. Toward office-based measurement of gastric emptying in symptomatic diabetics using [13C]octanoic acid breath test. Am J Gastroenterol 2000 95 : 2751 61.
27. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998 115 : 1346 52.
28. Chial HJ, Camilleri C, Delgado-Aros S et al. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil 2002 14 : 249 53.
29. Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci 2007 52 : 418 24.
30. Talley NJ, Camilleri M, Chitkara DK et al. Effects of desipramine and escitalopram on postprandial symptoms induced by the nutrient drink test in healthy volunteers: a randomized, double-blind, placebo-controlled study. Digestion 2005 72 : 97 103.
31. Clouse RE. Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial. Gastroenterology 2003 125 : 249 53.
32. Andresen V, Camilleri M. Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain. Neurogastroenterol Motil 2006 18 : 354 60.
33. Walker EA, Roy-Byrne PP, Katon WJ, Jemelka R. An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med 1991 21 : 245 52.
34. Otaka M, Jin M, Odashima M et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005 21 (Suppl. 2 42 6.
35. Mayer EA, Raybould HE. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 1990 99 : 1688 704.
36. Talley NJ, Van Zanten SV, Saez LR et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001 15 : 525 37.
37. Tack J, Caenepeel P, Corsetti M, Janssens J. Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology 2004 127 : 1058 66.
38. Kim SW, Shin IS, Kim JM et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006 47 : 440 2.
39. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995 40 : 86 95.
40. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994 8 : 159 66.
41. Namin F, Patel J, Lin Z et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil 2007 19 : 196 202.
42. Ghoos YF, Maes BD, Geypens BJ et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993 104 : 1640 7.
43. Punkkinen J, Konkka I, Punkkinen O, Korppi-Tommola T, Farkkila M, Koskenpato J. Measuring gastric emptying: comparison of 13C-octanoic acid breath test and scintigraphy. Dig Dis Sci 2006 51 : 262 7.
44. Talley NJ. Antidepressants in IBS: are we deluding ourselves? Am J Gastroenterol 2004 99 : 921 3.
45. Lee SY, Rho SH, Choi SC. Functional dyspepsia and mirtazapine. Can J Psychiatry 2002 47 : 582 3.